Form 4 for HRTX HERON THERAPEUTICS, INC. /DE/
Accepted 2025-05-02 00:00:00 ET · period of report 2025-04-30 · accession 0000950170-25-063061 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-02 | 2025-04-30 | HRTX | Collard Craig A | CEO, Dir | M - OptEx | — | +34.8K | 426.0K | +9% | — |
| D | 2025-05-02 | 2025-04-30 | HRTX | Collard Craig A | CEO, Dir | M - OptEx | $0.00 | -34.8K | 521.8K | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-30 | M | A | 34,789 | — | 425,952 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock. |
| 2 | Derivative | Restricted Stock Units | 2025-04-30 | M | D | 34,789 | $0.00 | 521,831 | D | $0.00 · — to — | 34,789 Common Stock | (F2) The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025). |